{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:37:40Z","timestamp":1782549460106,"version":"3.54.5"},"reference-count":21,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CLEP"],"DOI":"10.2147\/clep.s409791","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T03:15:27Z","timestamp":1687317327000},"page":"765-773","source":"Crossref","is-referenced-by-count":6,"title":["Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy\u2013Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Matthew D","family":"Galsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi S","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0305-3610","authenticated-orcid":true,"given":"Brian","family":"Bloudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Hepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Timmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Lenero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"ref1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Bladder Cancer. National Comprehensive Cancer Network; 2022. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed February 16, 2023."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2022.40.6_suppl.570","volume":"40","author":"Bloudek","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2022.40.6_suppl.487","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref5","unstructured":"Food and Drug Administration. Successes and Opportunities in Modeling and Simulation for FDA. Food and Drug Administration; 2022."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","volume":"177","author":"Viscardi","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/cancers12061449","volume":"12","author":"Mollica","year":"2020","journal-title":"Cancers."},{"key":"ref8","first-page":"S1","volume":"27","author":"Schwartz","year":"2021","journal-title":"J Manag Care Pharm"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.2147\/CLEP.S377093","volume":"14","author":"Bloudek","year":"2022","journal-title":"Clin Epidemiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1182\/blood-2021-147308","volume":"138","author":"Phillips","year":"2021","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"10791","DOI":"10.1182\/blood-2022-162573","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/blood-2021-148004","volume":"138","author":"Burke","year":"2021","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"ref16","volume-title":"C27. Real-World Avelumab Maintenance Eligibility and Treatment Patterns in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma","year":"2023"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref18","volume-title":"Simulating the Impact of First-Line Treatment Choice on Survival Among Patients with Locally Advanced\/Metastatic Urothelial Carcinoma Considered Cisplatin Ineligible","year":"2023"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(17)30242-5","volume":"18","author":"Garc\u00eda-Donas","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.19.03091","volume":"38","author":"Galsky","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S356","DOI":"10.1016\/j.jval.2022.09.1765","volume":"25","author":"Bloudek","year":"2022","journal-title":"Value Health"}],"container-title":["Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=90610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=90610","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T03:15:33Z","timestamp":1687317333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/benchmarking-maintenance-therapy-survival-in-first-line-platinum-based-peer-reviewed-fulltext-article-CLEP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2147\/clep.s409791","relation":{},"ISSN":["1179-1349"],"issn-type":[{"value":"1179-1349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}